Risk for at least one adverse event per patient · Apathy in people with mild‐to‐moderate Alzheimer's disease
Rivastigmine probably leads to higher incidence of adverse events (at least one adverse event by 26 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults, most with moderate to severe eczema
1 finding from 1 review
Serious adverse events (SAEs) start of surgery until 8 hours after surgery · adults undergoing intra‐ and transperitoneal laparoscopic procedures
It is very uncertain whether summary of findings table ‐ Deep neuromuscular blockade (NMB) changes serious adverse events (SAEs) start of surgery until 8 hours after… compared with moderate NMB (very low certainty).
1 finding from 1 review
Proportion of participants with one or more serious adverse events due to any cause · children and adults with predominantly mild to moderate asthma
Summary of findings table ‐ Vitamin D showed no clear difference in proportion of participants with one or more serious adverse events… compared with placebo (high certainty).
1 finding from 1 review
Primary: adverse events ‐ any adverse event treatment‐related (application site pruritus) · participants with moderate to severe hand eczema
Corticosteroid creams/ointments: clobetasol propionate foam showed no clear difference in primary: adverse events ‐ any adverse event treatment‐related… compared with vehicle foam (moderate certainty).
1 finding from 1 review
Adverse events: all grades · individuals with moderate or severe COVID‐19
Hyperimmune immunoglobulin from human plasma showed no clear difference in adverse events of any grade up to 28 days (data only available for… compared with saline placebo (low certainty).
1 finding from 1 review
RR 0.98 [0.81, 1.18]
Studies not reported
Low
Serious adverse events up to day 28 (data available only as a composite of serious adverse events or death up to day 28) · individuals with moderate or severe COVID‐19
Hyperimmune immunoglobulin from human plasma showed no clear difference in serious adverse events up to day 28 (data available only as a… compared with saline placebo (low certainty).
1 finding from 1 review
RR 0.72 [0.45, 1.14]
Studies not reported
Low
Serious adverse events "Defined as events that result in death, hospitalization, prolongation of hospitalization, or are life threatening (based on the judgment of the study physician)" (Quinn 2010) · Apathy in people with mild‐to‐moderate Alzheimer's disease
Omega‐3 PUFA supplements showed no clear difference in serious adverse events "Defined as events that result in death,… compared with placebo (high certainty).
1 finding from 1 review
Participants admitted to hospital because of respiratory adverse events (treatment period) · adults with asthma
Bronchial thermoplasty leads to higher participants admitted to hospital because of respiratory adverse… compared with any active control (high certainty).
1 finding from 1 review
Participants admitted to hospital because of respiratory adverse events (post‐treatment period) · adults with asthma
Bronchial thermoplasty showed no clear difference in participants admitted to hospital because of respiratory adverse… compared with any active control (moderate certainty).
1 finding from 1 review